{
    "paper_id": "5288fd536260ca6f5c55ba9f28926923da67898d",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": " [185] [186] [187] 186f, 186t Ascitic fluid infections, [190] [191] [192] [193] [194] 191t, [192] [193] [191] [192] 190 pathogenesis of, 191 prophylaxis of, [194] [195] [194] [195] 194, 194t risks for, [192] [193] [193] [194] ",
            "cite_spans": [
                {
                    "start": 1,
                    "end": 6,
                    "text": "[185]",
                    "ref_id": null
                },
                {
                    "start": 7,
                    "end": 12,
                    "text": "[186]",
                    "ref_id": null
                },
                {
                    "start": 13,
                    "end": 18,
                    "text": "[187]",
                    "ref_id": null
                },
                {
                    "start": 19,
                    "end": 24,
                    "text": "186f,",
                    "ref_id": null
                },
                {
                    "start": 25,
                    "end": 55,
                    "text": "186t Ascitic fluid infections,",
                    "ref_id": null
                },
                {
                    "start": 56,
                    "end": 61,
                    "text": "[190]",
                    "ref_id": null
                },
                {
                    "start": 62,
                    "end": 67,
                    "text": "[191]",
                    "ref_id": null
                },
                {
                    "start": 68,
                    "end": 73,
                    "text": "[192]",
                    "ref_id": null
                },
                {
                    "start": 74,
                    "end": 79,
                    "text": "[193]",
                    "ref_id": null
                },
                {
                    "start": 80,
                    "end": 85,
                    "text": "[194]",
                    "ref_id": null
                },
                {
                    "start": 86,
                    "end": 91,
                    "text": "191t,",
                    "ref_id": null
                },
                {
                    "start": 92,
                    "end": 97,
                    "text": "[192]",
                    "ref_id": null
                },
                {
                    "start": 98,
                    "end": 103,
                    "text": "[193]",
                    "ref_id": null
                },
                {
                    "start": 104,
                    "end": 109,
                    "text": "[191]",
                    "ref_id": null
                },
                {
                    "start": 110,
                    "end": 115,
                    "text": "[192]",
                    "ref_id": null
                },
                {
                    "start": 116,
                    "end": 136,
                    "text": "190 pathogenesis of,",
                    "ref_id": null
                },
                {
                    "start": 137,
                    "end": 156,
                    "text": "191 prophylaxis of,",
                    "ref_id": null
                },
                {
                    "start": 157,
                    "end": 162,
                    "text": "[194]",
                    "ref_id": null
                },
                {
                    "start": 163,
                    "end": 168,
                    "text": "[195]",
                    "ref_id": null
                },
                {
                    "start": 169,
                    "end": 174,
                    "text": "[194]",
                    "ref_id": null
                },
                {
                    "start": 175,
                    "end": 180,
                    "text": "[195]",
                    "ref_id": null
                },
                {
                    "start": 181,
                    "end": 185,
                    "text": "194,",
                    "ref_id": null
                },
                {
                    "start": 186,
                    "end": 201,
                    "text": "194t risks for,",
                    "ref_id": null
                },
                {
                    "start": 202,
                    "end": 207,
                    "text": "[192]",
                    "ref_id": null
                },
                {
                    "start": 208,
                    "end": 213,
                    "text": "[193]",
                    "ref_id": null
                },
                {
                    "start": 214,
                    "end": 219,
                    "text": "[193]",
                    "ref_id": null
                },
                {
                    "start": 220,
                    "end": 225,
                    "text": "[194]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Salmonella typhi infection, anomalous, gallbladder carcinoma and",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "134t-135t Saw palmetto, hepatotoxicity of, 134t-135t Schistosoma japonicum",
            "authors": [
                {
                    "first": "Hepatotoxicity",
                    "middle": [],
                    "last": "Sassafras",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Of",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "419--422",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Schistosoma species. see Schistosomiasis Schistosomiasis, 419t-422t, 430-431, 430f acute toxemic, 431 cirrhosis and, 158-159 granulomas due to, 374f",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "377",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF1": {
            "text": "Hematologic features, of cirrhosis, 161 Hematuria, Wilson disease and, 258 Hemochromatosis, 243-252. see also Hereditary hemochromatosis Hemolysis, acute intravascular, Wilson disease and, 259 Hemophagocytic lymphohistiocytosis, in children, 349 Hepatic abscesses. see Abscesses Hepatic adenoma, 383-384 Hepatic adenomatosis, 384 Hepatic artery, 294 Hepatic artery thrombosis (HAT), in liver transplantation, 467 Hepatic blood flow, decreased, 295-296 Hepatic blood supply, 294 Hepatic capillariasis, 419t-422t, 428 Hepatic circulation, 294 Hepatic crisis, in sickle cell disease, 330 Hepatic cysts. see Cyst(s) Hepatic 2,6-dimethyliminodiacetic acid (HIDA), for Severe acute respiratory syndrome (SARS), 82 Sevoflurane, hepatic metabolism of, 438 Sexual transmission, in hepatitis C virus, 67 Shigella species, 415 Shock liver, 26 postoperative jaundice due to, 451 Shou-wu-pian, hepatotoxicity of, 134t-135t Sicca complex, in primary biliary cholangitis, 224 Sicca syndrome, in primary biliary cholangitis, 229 Sickle cell disease, 325t, 330 in children, 348 Sideroblastic anemia , from trientine, 264 Silymarin, for mushroom poisoning, 154 Sirolimus, for liver transplantation, 465 Sj\u00f6gren syndrome, 325t, 328 Skin abnormalities, in primary biliary cholangitis, 225, 225f-226f Skin injury, drug-induced liver injury and, 138t-139t Skullcap, hepatotoxicity of, 134t-135t Smoking, alpha-1 antitrypsin deficiency and, 272 SOD (sphincter of Oddi dysfunction), 487 Sodium, ascites and, 188 Sodium benzoate, for hepatic encephalopathy, 214 Stent placement, long-term, for bile duct stones, 485 Stigmata, of chronic liver disease and/or cirrhosis, 163 Still disease, 327 Streptococcus anginosis, 400 Streptococcus pyogenes, 413-414 Strictures, dominant, due to primary sclerosing cholangitis, 241 Strongyloides stercoralis, 419t-422t, 428-429 Strongyloidiasis, 419t-422t, 428-429 Subacute liver failure, 18 Substance abuse, liver transplantation in, 460-461 Substrate reduction therapy, for Gaucher disease, 274 Succinylcholine, in liver disease, 439 Sufentanil, in liver disease, 438 Sulfadiazine, for toxoplasmosis, 426 Sulfamethoxazole-trimethoprim (SMX-TMP), druginduced liver injury due to, 140t-144t Sulfone syndrome, drug-induced liver injury and, 138t-139t Sunflower cataracts, in Wilson disease, 256, 258 Pugh classification of, 441-443, 442t MELD score for, 443-444, 444f with obstructive jaundice, 444-445 Sustained virologic response (SVR), in chronic hepatitis C, 75 Sweat chloride test, for cystic fibrosis, 277 SXR gene, in primary sclerosing cholangitis, 235 Symmers clay-pipe stem fibrosis, 377 Sympathetic nervous system (SNS), in hepatorenal syndrome, 198-199 Syo-saiko-to, hepatotoxicity of, 134t-135t Syphilis, 417-418 Systemic circulatory disturbances, in hepatorenal syndrome, 198 Systemic disease, liver in, 324-334, 325t Langerhans cell histiocytosis as, 349 cystic fibrosis as, 348 inborn errors of glycosylation as, 350 muscular dystrophies as, 350 PSC and inflammatory bowel disease as, 349 sickle cell disease as, 348 endocrine and metabolic disorders, 328 Systemic hypertension, in liver transplantation, 468 Systemic inflammation, in hepatorenal syndrome, 200 Systemic lupus erythematosus (SLE), 325t, 327-328 Systemic mastocytosis, 329 Systemic sclerosis, 325t, 328 T Tacrolimus for autoimmune hepatitis, 105, 106t for liver transplantation, 464 Tamoxifen, nonalcoholic fatty liver disease and, 124 Targeted molecular therapies, for hepatocellular carcinoma, 390 Taurine supplementation, for cystic fibrosis, 277 Telbivudine, for chronic hepatitis B, 59, 59t Tenofovir, for chronic hepatitis B, 59, 59t with HIV, 364 Terlipressin for acute variceal hemorrhage, 176-177, 177t for hepatorenal syndrome, 203-204, 203t Terry nails, due to cirrhosis, 162 Tertiary (late) syphilis, 418 Tfr2-related hemochromatosis, 244t TGR5 gene, in primary sclerosing cholangitis, 235 THC (transhepatic cholangiography), percutaneous Timolol, for recurrent variceal hemorrhage, 179t Tinidazole, for amebic liver abscess, 399 TIPS. see Transjugular intrahepatic portosystemic shunt (TIPS) TJP2 deficiency, in children, 339 Total parenteral nutrition in children, 348-349 drug-induced liver injury due to, 140t-144t postoperative jaundice due to, 451 Toxic liver disease, 130-157 Toxic shock syndrome, 413-414 Toxic shock syndrome toxin (TSST-1), 414 Toxins, and alcoholic liver disease, 112 Toxocara canis, 419t-422t, 427-428 Toxocara cati, 419t-422t, 427-428 Toxocariasis, 419t-422t, 427-428 granulomas in, 380 Toxoplasma gondii, 419t-422t, 426 Toxoplasmosis, 419t-422t, 426 Transcardiac membranotomy, for Budd-Chiari syndrome, 286 Transferrin, in pregnancy, 309t Transfusion transmitted (TT) virus, 82 Transhepatic cholangiography (THC), percutaneous of bile duct stones, 483-485 of cholangiocarcinoma, 509 of gallbladder carcinoma, 503 Transjugular biopsy, 13 Transjugular intrahepatic portosystemic shunt (TIPS) for ascites, preoperative, 448 for Budd-Chiari syndrome, 286 for chronic portal vein thrombosis, 289 for esophagogastric variceal hemorrhage acute, 178 recurrent, 179 for hepatorenal syndrome, 203, 205 for refractory ascites, 182, 189 Trematodes, 419t-422t, 430-434 clonorchiasis due to, 419t-422t, 433-434 fascioliasis due to, 419t-422t, 431-433, 432f opisthorchiasis due to, 419t-422t, 433-434 schistosomiasis due to, 419t-422t, 430-431, 430f Treponema pallidum, 417-418 Trichinella spiralis, 419t-422t, 429 Trichinosis, 419t-422t, 429 Triclabendazole, for fascioliasis, 433 Trientine, for Wilson disease, 264 with neurologic disease, 266 during pregnancy, 265, 318 Triglyceride, impaired synthesis of, in nonalcoholic fatty liver disease, 122-123 Tropical splenomegaly syndrome, 424 Tryptophan metabolites, in hepatic encephalopathy, hepatic adenoma as, 383-384 of mesenchymal origin, 386, 386t tumor-like lesions of hepatocytes as, 384-385 adenomatous hyperplasia (macroregenerative nodule, dysplastic nodule), 385 focal nodular hyperplasia, 384 nodular regenerative hyperplasia, 384-385 partial nodular transformation, 385 of biliary tract, 499-512 diagnostic approach to, 393, 393f in elderly, 358-359 malignant, 386-393 Tumor infiltration, hepatomegaly in children due to, 347 Tumor-like lesions, of hepatocytes, 384-385 adenomatous hyperplasia (macroregenerative nodule, dysplastic nodule) as, 385 focal nodular hyperplasia as, 384 nodular regenerative hyperplasia as, 384-385 partial nodular transformation as, 385 24-hour urine sodium collection, for ascites, 187 Type 2 diabetes mellitus, nonalcoholic fatty liver disease and, 124 of nonalcoholic fatty liver disease, 126 of portal venous thrombosis, 288 of primary biliary cholangitis, 227 Ultrasound. see Ultrasonography Ultrasound elastography, for cardiac hepatopathy, 305 Urea synthesis, 11 Uric acid, in pregnancy-associated liver disease, 312t Uridine diphosphate (UDP)-glucuronyl V Valerian, hepatotoxicity of, 134t-135t Valproic acid, drug-induced liver injury due to, 140t-144t van den Bergh reaction, 2 Vancomycin, for hepatic encephalopathy, 214 VAQTA, doses and schedules for, 41 Variceal wall tension, 175 Varicella zoster virus (VZV), 79t, 81 acute liver failure due to, 24-25 versus-host (GVH) disease vs., 291 pathogenesis of, 290-291 risk factors for, 290 splenic vein thrombosis, 287 Vascular injury, drug-induced liver injury and, 149t Vascular occlusion, acute liver failure due to, 25-26 Vascular reconstruction, in liver transplantation, 463 Vasoactive agents, for acute variceal hemorrhage, 177 Vasoconstrictor, for portal hypertension, 173 Vasoconstrictor factors, in hepatorenal syndrome, 198-200 Vasodilator, for portal hypertension, 173 Vasodilatory factors, in hepatorenal syndrome, 200 Vasopressin for acute variceal hemorrhage, 177 for portal hypertension, 173 Venous congestion, hepatomegaly in children due to, 344 Venous drainage, hepatic, 294 Venous outflow obstruction, in liver transplantation, 467 Venous outflow reconstruction, in liver transplantation, 463 Very-low-density lipoproteins, secretion of, in nonalcoholic fatty liver disease, 122-123 modes of transmission of, 64 pathogenesis and pathology of, 63 serologic and virologic tests for, 64 virology of, 63 in pregnancy, 319-321 Viral infections, liver involvement with, 79t Visceral larva migrans, 427 Visceral leishmaniasis, 419t-422t, 425-426 Vitamin A, for malabsorption, in primary biliary cholangitis, 229 Vitamin D, for malabsorption, in primary biliary cholangitis, 229 Vitamin deficiencies, fat-soluble, due to primary sclerosing cholangitis, 242 Vitamin E for malabsorption, in primary biliary cholangitis, 229 for nonalcoholic fatty liver disease, 128 Vitamin K deficiency, and prothrombin time, 8-9 for malabsorption, in primary biliary cholangitis, 229 preoperative, 447 Vomiting, in pregnancy, 309 von Meyenburg complex, 385 W Warfarin, for heart failure, with liver dysfunction, 306 WD gene, in copper metabolism, 255, 255f Wedged hepatic vein pressure (WHVP), 169 Weight loss, for nonalcoholic fatty liver disease, 128",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}